Who pays for the work
[FOUNDER TO SUPPLY: dated list of funds, grants, revenue, in-kind help and commercial ties; confirm none only where true]. An empty list does not prove that no funds were received.
Proposed rules
A drug maker may not pay for, edit or approve a page about its own product or class. Reviewers control their findings. Pay must not depend on a favorable result.
The proposed model has no ads or paid referral links to pharmacies, drug makers or telehealth firms. [FOUNDER TO SUPPLY: current arrangements and date these rules take effect]. Any change needs a clear notice before it starts.
We would list an unrestricted grant here and on the work it supports. “Unrestricted” means the funder has no control over the content. It does not bypass the ban on product or class funding.
The proposed annual report lists funding above $1,000. It also lists all product-linked support, no matter the amount. This is a reporting rule, not a claim about funds received.
Review pay and future plans
A reviewer may get a fixed fee for a defined task. We record pay and conflicts in the review record. See Medical review. We may offer services or licences to institutions. These are plans, not claims of sales or clients. [FOUNDER TO SUPPLY: actual offers and fees].
Questions
Report an undisclosed tie through Contact. We will keep dated policy versions. [VERIFY: legal review of industry, pharmacy or referral agreements].